Furthermore, Zhao [32] et al. found that the average Th2 cytokine (IL-4, IL-10) levels were higher in NSCLC patients before immunotherapy, and hence, DC/CIK could overcome the dominant status of Th2 cytokines and up-regulate the anti-tumor effect. This evidence concerns the gene IL10 and neoplasm.